Latest News and Press Releases
Want to stay updated on the latest news?
-
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...